Balentine LLC Incyte Corp Transaction History

Balentine LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $186,561 - $234,484	2,819 New	2,819 $214,000
Q3 2020 Nov 02, 2020	SELL	$85.07 - $109.69 $21,607 - $27,861	-254 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $1,780 - $2,614	24 Added 10.43%	254 $26,000
Q1 2020 May 18, 2020	BUY	$63.18 - $85.97 $13,330 - $18,139	211 Added 1110.53%	230 $17,000
Q4 2019 Sep 02, 2020	SELL	$73.04 - $95.72 $1,972 - $2,584	-27 Reduced 58.7%	19 $2,000
Q3 2019 Nov 15, 2019	BUY	$72.82 - $86.52 $2,912 - $3,460	40 Added 666.67%	46 $3,000
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $441 - $532	6 New	6 $1,000
Q1 2018 May 16, 2018	SELL	$83.06 - $100.98 $3,073 - $3,736	-37 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$109.15 - $138.27 $4,038 - $5,115	37	37 $4,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

Stay updated on Balentine LLC with notifications on news.